ArticleFrontiers in immunology2026

Development of a lipoprotein(a)-based model for predicting progression-free survival and grade3/4 adverse events in driver gene negative metastatic lung adenocarcinoma patients with PD-L1 TPS <50.

Sicong Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.